| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_223bfe142f5cc2d8cd68be66a0520382 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F16-211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-507 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2019-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2676324f76e1ab3662f83f04d740c305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecfcf495aa68806edcc84fe2cf917199 |
| publicationDate |
2021-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113167788-A |
| titleOfInvention |
Combined drug development method based on 3D human cancer model |
| abstract |
The present application relates to a method for characterizing a composition comprising two or more active pharmaceutical compounds, comprising the steps of: a) composition Selection Screening (CSS), in which candidate compositions containing two or more active pharmaceutical compounds are tested with one or more cell line derived 3D microtissues, and b) Composition Validation Screening (CVS), in which candidate compositions of step b) are tested with primary patient sample derived 3D microtissues. |
| priorityDate |
2018-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |